Latest gabapentin Stories
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into a definitive agreement to sell its Israeli based veterinary business unit to Phibro Animal Health Corporation, for total consideration of approximately $47 million.
Depomed, Inc. (Nasdaq:DEPO) today announced the presentation of data from its Phase 2 study of DM-5689 (formerly referred to as Gabapentin GR(R)) for the treatment of women with moderate-to-severe menopausal hot flashes.
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ProAir(R) HFA (albuterol sulfate) Inhalation Aerosol for use in patients as young as 4 years of age. Previously, ProAir HFA had been indicated for use in patients aged 12 and older.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the introduction of Nicardipine Hydrochloride Injection, 2.5 mg/mL, which is AP-rated to EKR Therapeutics' hypertension treatment Cardene(R) I.V.
Depomed, Inc. (NASDAQ: DEPO) today announced that president and chief executive officer, Carl A. Pelzel, will present on Tuesday, September 23, 2008 at 8:30 a.m. ET during the UBS Global Life Sciences Conference to be held in New York City.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced new data from the longest prospective study of treatment to relapsing-remitting multiple sclerosis (RRMS), which proves robust efficacy and safety of COPAXONE(R) (glatiramer acetate injection).
Depomed, a specialty pharmaceutical company, has announced the enrollment and dosing of the first patient in Breeze 1, the first of two pivotal Phase III clinical trials in Depomed's registration program for Gabapentin GR for the treatment of menopausal hot flashes.
Depomed, Inc. (NASDAQ:DEPO) announced today the enrollment and dosing of the first patient in Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration program for Gabapentin GR(R) for the treatment of menopausal hot flashes.
RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline and XenoPort, Inc. announced today that a New Drug Application (NDA) has been submitted to the U.S.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced presentations of several new studies at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal.
- A trick or prank.